Forge Therapeutics To Move New Class Of Antibiotics Into Clinical Development
The company’s technology uses a mechanism of action not found in existing antibiotics.
The San Diego Union-Tribune:
Forge Therapeutics Raises $15 Million For New Class Of Antibiotics
Forge Therapeutics, a developer of a new class of antibiotics, has raised $15 million in a Series A venture capital financing round. The money will advance its lead product into clinical development, said Zachary Zimmerman, CEO of the San Diego-based biotech company. Forge’s prospective antibiotic has broad-spectrum effectiveness against drug resistant gram-negative bacteria, an increasingly urgent matter of concern. Gram-negative bacteria include Carbapenem-resistant Enterobacteriaceae, or CRE; multidrug-resistant Pseudomonas aeruginosa; and drug-resistant Salmonella, both those that cause typhoid and which cause food poisoning. (Fikes, 5/1)